Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Treatment in the home and hospice of long-term care facilities, particularly for non-ambulatory patients, could provide significant advantages for patients and for the region. The Calgary Health Region has a unique resource in the home parenteral therapy program (HPTP). With the assistance of HPTP, patients requiring bisphosphonate treatment for the management of tumor-induced hypercalcemia (TIH) or malignant bone pain (MBP) could be treated in the community (ie at home). However, the resources required and the costs associated with community-based (homes, hospices, long-term care facilities) treatment of TIH and MBP need to be identified and evaluated so as to guide future regional decision making.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alberta Health Services
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

If hypercalcemic:

• Serum corrected Ca+++>= 2.5 mmol/L and symptomatic hypercalcemia

• Asymptomatic hypercalcemia with corrected Ca+++>= 3.0 mmol/L

• Moderate to severe intolerable pain (>=6/10 on numerical rating scale [NRS]) despite optimal treatments with a strong opioid such as morphine, hydromorphone, fentanyl, oxycodone or methadone

• Radiotherapy bone pain related to metastatic bone disease

Exclusion Criteria:

• Not on a regular bisphosphonate regimen